FindTrial
Sign In

A Study on the Efficacy andSafety of Superselective Ophthalmic Artery Chemotherapy in the Treatment of R-E V Grade Retinoblastoma

A Study on the Efficacy andSafety of Superselective Ophthalmic Artery Chemotherapy in the Treatment of R-E V Grade Retinoblastoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007373
Enrollment
Unknown
Registered
2015-10-08
Start date
2015-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Interventions

1:Intravenous 5mg melphalan per 4 week
2:Intravenous 7.5mg melphalan per 4 week

Sponsors

The General Hospital of Chinese Armed Police Forces
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for Reese-Ell sworth V grade; Aged from 0 to 18 years; Agreed with the protocol for this study and signed informed consent.

Exclusion criteria

Exclusion criteria: Participant in other clinical trials; Receiving other anti-cancer therapy; MRI showed the tumor metastasize to other organ; Abnormal cardiovascular, liver, or hematopoietic function; Other inadvisable reasons for this research.

Design outcomes

Primary

MeasureTime frame
Ocular Salvage;Tumor Response;—

Secondary

MeasureTime frame
Visual acutity;WBC;—

Countries

China

Contacts

Public ContactGengsheng Mao
mclxmgs@126.com+86 13901328116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026